Globally, cervical cancer is the fourth leading cause of cancer death in women, with an estimated 661,021 new cases and 348,189 deaths in 2022, with the highest rates recorded in countries with a low sociodemographic index. In Congo, a real public health problem, it is the second cancer in women after breast cancer. The main objective of this study was to estimate the overall survival of patients treated for locally advanced cervical cancer with concomitant radiochemotherapy (CCR) and followed at the Brazzaville University Hospital. Methods: This was a retrospective study of locally advanced cervical cancers that received treatment with RCC and were followed at the Brazzaville University Hospital between 2015 and 2024. Survival was estimated using the Kaplan-Meier method. The study of prognostic factors was done using the Log-Rank test for the comparison between different classes of the same variable and the Cox model for multivariate analysis. Results: A total of 43 cases of cervical cancer that benefited from RCC were collected at the Brazzaville University Hospital between 2015 and 2024. The mean age was 56.7 ± 13.8 years, with extremes of 31 and 84 years. Forty cases (93.2%) were discovered as a result of gynecological symptoms. Squamous cell carcinoma was found in 40 patients (93.02%). FIGO stage II was the most common (53.49%). All patients were treated with RCC and 8 (18.60%) received complementary brachytherapy. Twenty-two (51.16%) female patients died during the study period. The overall survival rate was 79.65% at 3 years and 51.6% at 5 years. The 3- and 5-year PFS were 67.11% and 36.74%, respectively. No significant prognostic factors were found in the cohort. Conclusion: The overall 5-year survival rate in cervical cancer patients treated with RCC in Brazzaville is relatively good. The results provide valuable information for research and policy development in the prevention and management of cervical cancer

References

1. Wu N., et al. “A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy”. Cancer Control: Journal of the Moffitt Cancer Center 28 (2021): 1073274821989307.
2. Mascarello KC., et al. “Survival analysis of women with cervical cancer treated at a referral hospital for oncology in Espírito Santo State, Brazil, 2000-2005”. Cad Saúde Pública 29 (2013): 823‑831.
3. Tshewang U., et al. “Survival Analysis of Cervical Cancer Patients: A Case Study of Bhutan”. Asian Pacific Journal of Cancer Prevention APJCP9 (2021): 2987‑2993.
4. Mapoko BSE., et al. “Epidemiological and clinical aspects of cervical cancers in Cameroon: experience of the Douala General Hospital”. Pan African Medical Journal 42 (2022): 109.
5. Ngatali CFS., et al. “Epidemiological Clinical and Histological Aspects of Gynecological and Breast Cancer in Pointe Noire (Congo Brazzaville)”. Advances in Breast Cancer Research 2 (2022): 89‑100.
6. Joko-Fru WY., et al. “Cancer survival in sub-Saharan Africa (SURVCAN-3): a population-based study”. Lancet Global Health 6 (2024): e947‑959.
7. Abrenica JKB and Bagadiong JG. “ EP237 Survival Outcome and Disease-Free Survival of Locally Advanced Cervical Cancer with CT-Detected Para-Aortic Lymph Nodes”. Philipp Journal Gynecologic Oncology 1 (1998): 14‑18.
8. Sanz-Garcia E., et al. “Impact of Demographic Characteristics, Staging Methods and Treatment in a European Locally Advanced Cervical Cancer (Lacc) Population”. Annals of Oncology 25 (2014): iv320.
9. Chopra S., et al. “Locally advanced cervical cancer: a study of 5-year outcomes”. Indian Journal Cancer1 (2018): 45‑49.
10. World Bank Open Data. World Bank Open Data.
11. Berraho M., et al. “Cervical cancer in Morocco: epidemiological profile from two main oncological centers”. Asian Pacific Journal of Cancer Prevention 7 (2012): 3153‑3137.
12. Crosbie EJ., et al. “Human papillomavirus and cervical cancer”. The Lancet9895 (2013): 889‑899.
13. Chaouki N., et al. “The viral origin of cervical cancer in Rabat, Morocco”. International Journal of Cancer 4 (1998): 546‑54.
14. Bermime Y and Benzidan M. “Premarital sexuality and gender in Morocco”. International Journal of Social Science Research (IJSSR) 5 (2022): 401.
15. Anolue FC., et al. “Carcinoma of the cervix at a university teaching hospital in Eastern Nigeria”. Nigerian Journal of Surgical Sciences 2 (2014): 49.
16. Elmajjaoui S., et al. “Epidemiology and outcome of cervical cancer in national institute of Morocco”. BMC Womens Health1 (2016): 62.
17. Allali M., et al. “Cervical cancer in Morocco: a literature review on risk factors, prevalence, and healthcare challenges”. Pan African Medical Journal 11 (2025).
18. Berraho M., et al. “HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study”. BMC Cancer1 (2021): 435.
19. Clark LH., et al. “Extremes in body mass index affect overall survival in women with cervical cancer”. Gynecologic Oncology 3 (2016): 497‑500.
20. Chen J., et al. “Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies”. Nutrition and Cancer 4 (2023): 1051‑1064.
21. Marita A., et al. “Long-term survival following neoadjuvant chemotherapy and concomitant radiochemotherapy in locally advanced cervical cancer: results of the Oncology Institute « Prof. Dr. Ion Chiricuta experience”. Journal of Medicine and Life 1 (2018): 42‑50.
22. Cantu-de Leon D., et al. “445 Impact of age on cancer specific survival in patients with locally advanced cervical cancer”. International Journal of Gynecological Cancer 30 (2020): A17‑18.
23. Yazghich I and Berraho M. “Cervical cancer in the Maghreb country (Morocco-Algeria-Tunisia): epidemiological, clinical profile and control policy”. La Tunisie Médicale 10‑11 (1998): 647‑657.
24. Enow-Orock G., et al. “Gynecological cancer profile in the Yaounde population, Cameroon”. Clinical Mother Child Health1 (2006): 437‑444.
25. Sando Z., et al. “Profile of gynecological and breast cancers in Yaoundé-Cameroon”. Pan African Medical Journal1 (2014).
26. Vale CL., et al. “Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials”. Journal of Clinical Oncology 35 (2008): 5802‑5812.
27. Maranga IO., et al. “Analysis of Factors Contributing to the Low Survival of Cervical Cancer Patients Undergoing Radiotherapy in Kenya”. PLOS ONE10 (2013): e78411.
28. Kawaguchi R., et al. “Prognostic Factors in Patients with Locally Advanced Uterine Cervical Cancer Treated with Radiotherapy as a Primary Treatment”. Annals of Oncology 23 (2012): xi126.
29. Khalkhali HR., et al. “Ten years’ survival in patients with cervical cancer and related factors in West Azerbaijan Province: Using of cox proportion hazard model”. Asian Pacific Journal of Cancer Prevention APJCP 5 (2019): 1345.
30. Moore KN., et al. “Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis”. Gynecologic Oncology 2 (2016): 294‑301.
31. Liu J., et al. “Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy”. Radiation Oncology 1 (2022): 142.
32. Kurohara SS., et al. “Influence of gravidity on prognosis in the common uterine cancers”. Cancer 5 (1971): 1117‑1120.
33. Kurohara SS., et al. “Relation of gravidity and age to prognosis and clinical stage in uterine cervix cancer”. Cancer1 (1970): 39‑45.

Citation

Citation: Nkoua Epala Brice Aymard., et al. “Survival of Patients Treated for Locally Advanced Cervical Cancer with Concomitant Radiochemotherapy and Followed at the Brazzaville University Hospital".Acta Scientific Cancer Biology 9.3 (2025): 58-64.

Copyright

Copyright: © 2025 Nkoua Epala Brice Aymard., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.